Transdermal drug delivery systems and their potential in alzheimer’s disease management
CNS and Neurological Disorders - Drug Targets, cilt.19, sa.5, ss.360-373, 2020 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 19 Sayı: 5
- Basım Tarihi: 2020
- Doi Numarası: 10.2174/1871527319666200618150046
- Dergi Adı: CNS and Neurological Disorders - Drug Targets
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, Biotechnology Research Abstracts, EMBASE, MEDLINE
- Sayfa Sayıları: ss.360-373
- Anahtar Kelimeler: Transdermal, Alzheimer's disease, drug delivery systems, cholinesterase inhibitors, N-methyl-D-aspartate antagonists, neuropathological disease
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Alzheimer's disease is a neuropathological disease with symptoms such as language prob-lems, confusion as to place or time, loss of interest in activities, which were previously enjoyed, be-havioral changes, and memory loss. Alzheimer's disease and other types of dementia affect almost 46.8 million people globally and are estimated to strike about 131.5 million people in 2050. It has been reported that Alzheimer's is the sixth main cause of mortality. The most used drugs, which are current-ly approved by the Food, and Drug Administration for Alzheimer’s disease are donepezil, rivastig-mine, galantamine, memantine, and the combination of donepezil and memantine. However, most of the drugs present various adverse effects. Recently, the transdermal drug delivery route has gained increasing attention as an emerging tool for Alzheimer's disease management. Besides, transdermal drug delivery systems seem to provide hope for the management of various diseases, due to the advantages that they offer in comparison with oral dosage forms. Herein, the current advancements in transdermal studies with potent features to achieve better Alzheimer's disease management are presented. Many researchers have shown that the transdermal systems provide higher efficiency since the first-pass he-patic metabolism effect can be avoided and a prolonged drug release rate can be achieved. In sum-mary, the transdermal administration of Alzheimer's drugs is an interesting and promising topic, which should be further elaborated and studied.